Table 3. Pooled HRs or RRs, heterogeneities and public cation biases of meta-analyses and subgroup analyses.
| No. of studies | HR (95%CI) or RR (95%CI)a | HR and RRP value | HeterogeneityP value | I2 value (%) | Bias P value | |
|---|---|---|---|---|---|---|
| OS | 19 | |||||
| High ABCB1 expression | 15 | 1.54 (1.25–1.90) | 0.000 | 0.267 | 18.0 | 0.078 |
| ABCB1 detected by IHC | 11 | 1.63 (1.22–2.19) | 0.000 | 0.151 | 43.4 | 0.206 |
| ABCB1 detected by by PCR | 4 | 1.42 (1.08–1.88) | 0.019 | 0.155 | 26.7 | 0.171 |
| FIGO III-IV | 2 | 1.92 (1.20–3.07) | 0.006 | 0.739 | 0.0 | - |
| Serous tumor | 3 | 1.26 (0.99–1.61) | 0.061 | 0.166 | 44.2 | 0.766 |
| ABCB1 expression in primary tumor | 10 | 1.33 (1.00–1.78) | 0.049 | 0.580 | 0.0 | 0.888 |
| ABCB1 expression in recurrent tumor | 3 | 3.09 (1.79–5.34) | 0.000 | 0.136 | 49.9 | 0.182 |
| Platinum-based chemotherapy | 14 | 1.54 (1.25–1.90) | 0.000 | 0.155 | 26.7 | 0.078 |
| Taxane-containing chemotherapyb | 5 | 1.33 (0.95–1.85) | 0.093 | 0.102 | 45.5 | 0.613 |
| Non-taxane-containing chemotherapyc | 3 | 2.55 (1.60–4.05) | 0.000 | 0.445 | 0.0 | 0.311 |
| All chemotherapyd | 6 | 1.48 (1.07–2.03) | 0.017 | 0.491 | 0.0 | 0.505 |
| Geographical region | ||||||
| America | 3 | 1.68 (1.16–2.44) | 0.006 | 0.156 | 42.6 | 0.957 |
| Asia | 5 | 1.16 (0.83–1.64) | 0.382 | 0.434 | 0.0 | 0.104 |
| Europe | 5 | 2.55 (1.57–4.13) | 0.000 | 0.650 | 0.0 | 0.327 |
| Oceania | 1 | 1.20 (0.92–1.56) | 0.171 | - | - | - |
| High ABCB1 expression adjusted for residual disease | 4 | 1.94 (1.52–2.46) | 0.000 | 0.000 | 86.4 | 0.080 |
| ABCB1 gene variants | 6 | 0.95 (0.99–1.02) | 0.989 | 0.053 | 54.1 | 0.748 |
| PFS | 19 | |||||
| High ABCB1 expression | 12 | 1.49 (1.22–1.82) | 0.000 | 0.000 | 73.6 | 0.146 |
| ABCB1 detected by IHC | 8 | 1.37 (1.05–1.79) | 0.042 | 0.000 | 81.3 | 0.122 |
| ABCB1 detected by by PCR | 4 | 1.67 (1.24–2.26) | 0.001 | 0.099 | 52.1 | 0.123 |
| FIGO III-IV | 3 | 1.97 (1.40–2.78) | 0.000 | 0.000 | 88.0 | 0.068 |
| Serous tumor | 2 | 1.14 (0.82–1.59) | 0.431 | 0.323 | 35.8 | - |
| Platinum-based chemotherapy | 12 | 1.49 (1.22–1.82) | 0.000 | 0.000 | 73.6 | 0.146 |
| Taxane-containing chemotherapyb | 3 | 1.30 (0.91–1.85) | 0.148 | 0.431 | 0.0 | 0.902 |
| Non-taxane-containing chemotherapyc | 5 | 1.91 (1.46–2.50) | 0.000 | 0.000 | 88.6 | 0.110 |
| All chemotherapyd | 4 | 1.39 (0.97–1.99) | 0.074 | 0.027 | 64.7 | 0.663 |
| Geographical region | ||||||
| America | 1 | 0.95 (0.48–1.88) | 0.883 | - | - | - |
| Asia | 3 | 2.04 (1.30–3.18) | 0.002 | 0.907 | 0.0 | 0.119 |
| Europe | 6 | 1.27 (0.92–1.75) | 0.141 | 0.000 | 87.6 | - |
| Oceania | 2 | 1.34 (1.10–1.62) | 0.003 | 0.732 | 0.0 | 0.199 |
| High ABCB1 expression adjusted for residual disease | 4 | 2.13 (1.60–2.83) | 0.000 | 0.000 | 85.4 | 0.003 |
| ABCB1 gene variants | 4 | 0.95 (0.81–1,12) | 0.555 | 0.003 | 78.4 | 0.582 |
| TR | 21 | |||||
| High ABCB1 expression | 21 | 0.63 (0.54–0.75) | 0.000 | 0.000 | 66.6 | 0.019 |
| ABCB1 detected by IHC | 16 | 0.63 (0.52–0.75) | 0.000 | 0.000 | 72.4 | 0.051 |
| ABCB1 detected by by PCR | 4 | 0.52 (0.33–0.80) | 0.003 | 0.214 | 33.0 | 0.464 |
| FIGO III-IV | 13 | 0.57 (0.47–0.68) | 0.000 | 0.000 | 69.9 | 0.010 |
| Serous tumor | 4 | 0.72 (0.57–0.91) | 0.006 | 0.024 | 68.1 | 0.823 |
| Platinum-based chemotherapy | 21 | 0.63 (0.54–0.75) | 0.000 | 0.000 | 63.7 | 0.019 |
| Taxane-containing chemotherapyb | 5 | 0.76 (0.49–1.16) | 0.199 | 0.164 | 38.7 | 0.032 |
| Non-taxane-containing chemotherapyc | 13 | 0.59 (0.48–0.72) | 0.000 | 0.000 | 73.2 | 0.032 |
| All chemotherapyd | 3 | 0.82 (0.53–1.28) | 0.389 | 0.180 | 41.6 | 0.171 |
| Geographical region | ||||||
| America | 2 | 0.85 (0.46–1.54) | 0.587 | 0.024 | 80.3 | - |
| Asia | 9 | 0.62 (0.46–0.85) | 0.003 | 0.271 | 19.4 | 0.133 |
| Europe | 10 | 0.62 (0.51–0.76) | 0.000 | 0.000 | 77.2 | 0.547 |
a: HR and its 95%CI were used to assess OS and PFS, RR and its 95%CI were used to assess TR
b: PT (platinum + taxane) regimen
c: PAC (platinum + doxorubicin + cyclophosphamide), PA (platinum + doxorubicin) or PC (platinum + cyclophosphamide) regimen
d:Studies identified patients received PT, PAC, PA or PC regimen.